Association Between Initial Route of Fluoroquinolone Administration and Outcomes in Patients Hospitalized for Community-acquired Pneumonia | Zendy

Raquel Belforti | Zendy; Tara Lagu | Zendy; Sarah Haessler | Zendy; Peter K. Lindenauer | Zendy; Penelope S. Pekow | Zendy; Aruna Priya | Zendy; Marya D. Zilberberg | Zendy; Daniel J. Skiest | Zendy; Thomas L. Higgins | Zendy; Mihaela Stefan | Zendy; Michael B. Rothberg | Zendy

Open Access

Association Between Initial Route of Fluoroquinolone Administration and Outcomes in Patients Hospitalized for Community-acquired Pneumonia

Author(s) -

Raquel Belforti,

Tara Lagu,

Sarah Haessler,

Peter K. Lindenauer,

Penelope S. Pekow,

Aruna Priya,

Marya D. Zilberberg,

Daniel J. Skiest,

Thomas L. Higgins,

Mihaela Stefan,

Michael B. Rothberg

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw209

Subject(s) - medicine , odds ratio , community acquired pneumonia , intensive care unit , confidence interval , pneumonia , propensity score matching , retrospective cohort study , levofloxacin , antibiotics , microbiology and biotechnology , biology

Fluoroquinolones have equivalent oral and intravenous bioavailability, but hospitalized patients with community-acquired pneumonia (CAP) generally are treated intravenously. Our objectives were to compare outcomes of hospitalized CAP patients initially receiving intravenous vs oral respiratory fluoroquinolones.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research